By Jonathan Stempel and Tina Bellon
July 20 (Reuters) - Bayer AG
The decision by the California Court of Appeal came after a San Francisco jury had in August 2018 awarded $289.2 million to the plaintiff Dewayne Johnson for his non-Hodgkin's lymphoma, a sum later cut by the trial judge to $78.5 million.
Johnson's case is separate from Bayer's agreement on June 24 to pay up to $10.9 billion to settle nearly 100,000 lawsuits in the United States linking glyphosate-based Roundup to cancer.
If upheld, the verdict and payout could make it harder for Bayer to resolve lawsuits by other plaintiffs.
The German drugs and pesticides company inherited liability for the lawsuits when it bought Monsanto Co, which had produced Roundup, for $63 billion in 2018.
In a statement, Bayer called Monday's decision "a step in the right direction" but said it may appeal to the California Supreme Court, calling the verdict inconsistent with the evidence and the law.
Bayer has long said regulators have deemed glyphosate safe. "We continue to stand strongly behind the safety and utility of Roundup," the company said.
In its 86-page decision, the appeals court said Johnson offered "abundant" evidence that glyphosate, together with other ingredients in Roundup products, caused his cancer.
But it said the payout must be reduced because California law did not afford damages for a shortened life expectancy.
Johnson's lawyer R. Brent Wisner called the decision another major victory for his client, who is known as Lee, despite the reduced damages.
"That Lee will not live an entire life with his wife and children should be compensable," he said. "Hopefully, when this issue gets before the California Supreme Court, we can change this irrational law."
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^> (Reporting by Jonathan Stempel and Tina Bellon in New York; Editing by Lisa Shumaker) ((firstname.lastname@example.org; +1 646 223 6317; Reuters Messaging: email@example.com)) Keywords: BAYER GLYPHOSATE/LAWSUIT (PIX)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.